Q-omics provides the consensus-scored TRIM29 profile across patient tissues and cancer cell-line models. TRIM29 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, TRIM29 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, TRIM29 protein abundance shows 22,859 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight LUAD, COAD, and HNSC as cancer lineages where TRIM29 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM29 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM29 survival associations across molecular data types. TRIM29 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM29 RNA expression–survival associations across cancer types. High TRIM29 expression shows unfavorable associations in LUAD, SKCM, KIRC and PAAD, but favorable associations in SARC and THCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for TRIM29 RNA expression.
This table summarizes TRIM29 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TRIM29. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM29 shows lower tumor expression in KIRC and KICH and higher tumor expression in COAD, LUSC, THCA and READ. The COAD box plot shows higher TRIM29 RNA expression in tumor versus normal tissue (log2 FC = +4.351, t-test p < 0.001).
This table shows molecular features associated with TRIM29 in patient tissues and cancer cell lines. In patient samples, TRIM29 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM29 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and URINARY_TRACT.
